Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value

REFERENCES

1. 1.↵
   2. Wen PY,
   3. Kesari S

   . Malignant gliomas in adults. N Engl J Med 2008;359:492–507

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Brandes AA,
   3. Tosoni A,
   4. Spagnolli F, et al

   . Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 2008;10:361–67

   Abstract/FREE Full Text
3. 3.↵
   2. Jeon HJ,
   3. Kong DS,
   4. Park KB, et al

   . Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience. Clin Neurol Neurosurg 2009;111:679–82

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Stupp R,
   3. Mason WP,
   4. van den Bent MJ, et al

   ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Wen PY,
   3. Macdonald DR,
   4. Reardon DA, et al

   . Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 2010;28:1963–72

   Abstract/FREE Full Text
6. 6.↵
   2. Cairncross JG,
   3. Macdonald DR,
   4. Pexman JH, et al

   . Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 1988;38:724–26

   Abstract/FREE Full Text
7. 7.↵
   2. Finn MA,
   3. Blumenthal DT,
   4. Salzman KL, et al

   . Transient postictal MRI changes in patients with brain tumors may mimic disease progression. Surg Neurol 2007;67:246–50; discussion 250

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Henegar MM,
   3. Moran CJ,
   4. Silbergeld DL

   . Early postoperative magnetic resonance imaging following nonneoplastic cortical resection. J Neurosurg 1996;84:174–79

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Kumar AJ,
   3. Leeds NE,
   4. Fuller GN, et al

   . Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217:377–84

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Ulmer S,
    3. Braga TA,
    4. Barker FG 2nd., et al

    . Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology 2006;67:1668–70

    Abstract/FREE Full Text
11. 11.↵
    2. Watling CJ,
    3. Lee DH,
    4. Macdonald DR, et al

    . Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 1994;12:1886–89

    Abstract/FREE Full Text
12. 12.↵
    2. Brandsma D,
    3. Stalpers L,
    4. Taal W, et al

    . Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453–61

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Chaskis C,
    3. Neyns B,
    4. Michotte A, et al

    . Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol 2009;72:423–28

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Taal W,
    3. Brandsma D,
    4. de Bruin HG, et al

    . Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113:405–10

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Abdel Razek AA,
    3. Kandeel AY,
    4. Soliman N, et al

    . Role of diffusion-weighted echo-planar MR imaging in differentiation of residual or recurrent head and neck tumors and posttreatment changes. AJNR Am J Neuroradiol 2007;28:1146–52

    Abstract/FREE Full Text
16. 16.↵
    2. Asao C,
    3. Korogi Y,
    4. Kitajima M, et al

    . Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. AJNR Am J Neuroradiol 2005;26:1455–60

    Abstract/FREE Full Text
17. 17.↵
    2. Chu HH,
    3. Choi SH,
    4. Ryoo I, et al

    . Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. Radiology 2013;269:831–40

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Hein PA,
    3. Eskey CJ,
    4. Dunn JF, et al

    . Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 2004;25:201–09

    Abstract/FREE Full Text
19. 19.↵
    2. Lee WJ,
    3. Choi SH,
    4. Park CK, et al

    . Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade glioma. Acad Radiol 2012;19:1353–61

    CrossRefPubMed
20. 20.↵
    2. Matsusue E,
    3. Fink JR,
    4. Rockhill JK, et al

    . Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 2010;52:297–306

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Song YS,
    3. Choi SH,
    4. Park CK, et al

    . True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis. Korean J Radiol 2013;14:662–72

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Cha J,
    3. Kim ST,
    4. Kim HJ, et al

    . Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis. AJNR Am J Neuroradiol 2014;35:1309–17

    Abstract/FREE Full Text
23. 23.↵
    2. Mullins ME,
    3. Barest GD,
    4. Schaefer PW, et al

    . Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. AJNR Am J Neuroradiol 2005;26:1967–72

    Abstract/FREE Full Text
24. 24.↵
    2. Young RJ,
    3. Gupta A,
    4. Shah AD, et al

    . Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology 2011;76:1918–24

    Abstract/FREE Full Text
25. 25.↵
    2. Man MZ,
    3. Dyson G,
    4. Johnson K, et al

    . Evaluating methods for classifying expression data. J Biopharm Stat 2004;14:1065–84

    CrossRefPubMed
26. 26.↵
    2. Kyritsis AP,
    3. Levin VA,
    4. Yung WK, et al

    . Imaging patterns of multifocal gliomas. Eur J Radiol 1993;16:163–70

    CrossRefPubMed
27. 27.↵
    2. Sneed PK,
    3. Gutin PH,
    4. Larson DA, et al

    . Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 1994;29:719–27

    CrossRefPubMed
28. 28.↵
    2. Milano MT,
    3. Okunieff P,
    4. Donatello RS, et al

    . Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 2010;78:1147–55

    CrossRefPubMed
29. 29.↵
    2. Ogura K,
    3. Mizowaki T,
    4. Arakawa Y, et al

    . Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution. Radiat Oncol 2013;8:97

    CrossRefPubMed
30. 30.↵
    2. McGeachie RE,
    3. Gold LH,
    4. Latchaw RE

    . Periventricular spread of tumor demonstrated by computed tomography. Radiology 1977;125:407–10

    CrossRefPubMed
31. 31.↵
    2. Ammirati M,
    3. Chotai S,
    4. Newton H, et al

    . Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme. J Clin Neurosci 2014;21:633–37

    CrossRefPubMed
32. 32.↵
    2. Burnet NG,
    3. Jena R,
    4. Burton KE, et al

    . Clinical and practical considerations for the use of intensity-modulated radiotherapy and image guidance in neuro-oncology. Clin Oncol (R Coll Radiol) 2014;26:395–406

    CrossRefPubMed